[68Ga]Ga-PSMA-11 PET/CT for monitoring response to treatment in metastatic prostate cancer: is there any added value over standard follow-up?

by Jonathan Kuten, David Sarid, Ofer Yossepowitch, Nicola J. Mabjeesh, Einat Even-Sapir
Published 2019-08-01

68Ga-PSMA-11 PET/CT Follow-Up of Patients with Prostate Cancer with Bone Metastases Who Had Reduced Bone Density after Androgen Deprivation Therapy

by Mikhail Kesler, Ido Druckmann, Charles Levine, Jonathan Kuten, Ofer Yossepowitch, Einat Even-Sapir
Published 2021-02-01

The significance of equivocal bone findings in staging PSMA imaging in the preoperative setting: validation of the PSMA-RADS version 1.0

by Jonathan Kuten, Snir Dekalo, Ishai Mintz, Ofer Yossepowitch, Roy Mano, Einat Even-Sapir
Published 2021-01-01

Personalized radiation dosimetry for PRRT—how many scans are really required?

by Nanette Freedman, Mattias Sandström, Jonathan Kuten, Natan Shtraus, Inna Ospovat, Albert Schlocker, Einat Even-Sapir
Published 2020-05-01

[18F] FDOPA PET may confirm the clinical diagnosis of Parkinson's disease by imaging the nigro-striatal pathway and the sympathetic cardiac innervation: Proof-of-concept study

by Jonathan Kuten, Adi Linevitz, Hedva Lerman, Nanette Freedman, Meir Kestenbaum, Tamara Shiner, Nir Giladi, Einat Even-Sapir
Published 2020-09-01

DaT-SPECT assessment depicts dopamine depletion among asymptomatic G2019S LRRK2 mutation carriers.

by Moran Artzi, Einat Even-Sapir, Hedva Lerman Shacham, Avner Thaler, Avi Orr Urterger, Susan Bressman, Karen Marder, Talma Hendler, Nir Giladi, Dafna Ben Bashat, Anat Mirelman
Published 2017-01-01

FDG PET Parkinson’s disease-related pattern as a biomarker for clinical trials in early stage disease

by Dawn C. Matthews, Hedva Lerman, Ana Lukic, Randolph D. Andrews, Anat Mirelman, Miles N. Wernick, Nir Giladi, Stephen C. Strother, Karleyton C. Evans, Jesse M. Cedarbaum, Einat Even-Sapir
Published 2018-01-01